Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

References

• ACS. Cancer Facts & Figures 2007
   Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56:106 - 130; PMID: 16514137; http://dx.doi.org/10.3322/canjclin.56.2.106
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9:153 - 166; PMID: 19238148; http://dx.doi.org/10.1038/nrc2602
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36 - 43; PMID: 19370178
   PubMed Web of Science ®Google Scholar
• Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010; 9:2344 - 2353; PMID: 20663931; http://dx.doi.org/10.1158/1535-7163.MCT-10-0324
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Bannerji R, Small K, Black S, Statkevich P, Abutarif M, et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies. J Clin Oncol 2008; 26 suppl abstr 3532
   Google Scholar
• Nemunaitis M, Saltzman M, Rosenberg MA, Khaira D, Small K, Kirschmeier P, et al. A phase I doseescalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Clin Oncol 2009; 27 suppl abstr 3535
   Google Scholar
• Hamad NM, Elconin JH, Karnoub AE, Bai W, Rich JN, Abraham RT, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002; 16:2045 - 2057; PMID: 12183360; http://dx.doi.org/10.1101/gad.993902
   PubMed Web of Science ®Google Scholar
• Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005; 7:533 - 545; PMID: 15950903; http://dx.doi.org/10.1016/j.ccr.2005.04.030
   PubMed Web of Science ®Google Scholar
• Lim KH, O'Hayer K, Adam SJ, Kendall SD, Campbell PM, Der CJ, et al. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol 2006; 16:2385 - 2394; PMID: 17174914; http://dx.doi.org/10.1016/j.cub.2006.10.023
   PubMed Web of Science ®Google Scholar
• Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res 2010; 70:4460 - 4469; PMID: 20484029; http://dx.doi.org/10.1158/0008-5472.CAN-09-1107
   PubMed Web of Science ®Google Scholar
• Jimeno A, Feldmann G, Suarez-Gauthier A, Rasheed Z, Solomon A, Zou GM, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8:310 - 314; PMID: 19174553; http://dx.doi.org/10.1158/1535-7163.MCT-08-0924
   PubMed Web of Science ®Google Scholar
• Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006; 12:4652 - 4661; PMID: 16899615; http://dx.doi.org/10.1158/1078-0432.CCR-06-0113
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403 - 2413; PMID: 9196156
   PubMed Web of Science ®Google Scholar
• Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 1999; 85:1261 - 1268; PMID: 10189130; http://dx.doi.org/10.1002/(SICI)1097-0142(19990315)85:6<1261::AIDCNCR7>3.3.CO;2-K
   PubMed Web of Science ®Google Scholar
• Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 2008; 68:2841 - 2849; PMID: 18413752; http://dx.doi.org/10.1158/0008-5472.CAN-07-5200
   PubMed Web of Science ®Google Scholar
• Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 2009; 15:2291 - 2301; PMID: 19258443; http://dx.doi.org/10.1158/1078-0432.CCR-08-2004
   PubMed Web of Science ®Google Scholar
• Truty MJ, Urrutia R. Basics of TGFbeta and pancreatic cancer. Pancreatology 2007; 7:423 - 435; PMID: 17898532; http://dx.doi.org/10.1159/000108959
   PubMed Web of Science ®Google Scholar
• Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn 2008; 10:111 - 122; PMID: 18258927; http://dx.doi.org/10.2353/jmoldx.2008.070115
   PubMed Web of Science ®Google Scholar
• De La O JP, Murtaugh LC. Notch signaling: where pancreatic cancer and differentiation meet?. Gastroenterology 2009; 136:1499 - 1502; PMID: 19327730; http://dx.doi.org/10.1053/j.gastro.2009.03.022
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321:1801 - 1806; PMID: 18772397; http://dx.doi.org/10.1126/science.1164368
   PubMed Web of Science ®Google Scholar
• Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008; 3:157 - 188; PMID: 18039136; http://dx.doi.org/10.1146/annurev.pathmechdis.3.121806.154305
   PubMed Web of Science ®Google Scholar
• Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55:3810 - 3816; PMID: 7641198
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243 - 247; PMID: 12242156; http://dx.doi.org/10.1016/S1535-6108(02)00122-8
   PubMed Web of Science ®Google Scholar
• Hirano T, Shino Y, Saito T, Komoda F, Okutomi Y, Takeda A, et al. Dominant negative MEKK1 inhibits survival of pancreatic cancer cells. Oncogene 2002; 21:5923 - 5928; PMID: 12185592; http://dx.doi.org/10.1038/sj.onc.1205643
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430 - 1438; PMID: 15084616; http://dx.doi.org/10.1200/JCO.2004.10.112
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999 - 2009; PMID: 12490681; http://dx.doi.org/10.1056/NEJMoa021967
   PubMed Web of Science ®Google Scholar
• Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7:278; PMID: 17074082; http://dx.doi.org/10.1186/1471-2164-7-278
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545 - 15550; PMID: 16199517; http://dx.doi.org/10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267 - 273; PMID: 12808457; http://dx.doi.org/10.1038/ng1180
   PubMed Web of Science ®Google Scholar
• De La O JP, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB, et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008; 105:18907 - 18912; PMID: 19028876; http://dx.doi.org/10.1073/pnas.0810111105
   PubMed Web of Science ®Google Scholar
• Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma SV, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009; 136:1741 - 1796; PMID: 10.1053/j.gastro.2009.01.008
   PubMed Web of Science ®Google Scholar
• Mythreye K, Blobe GC. The type III TGFbeta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 2009; 106:8221 - 8226; PMID: 19416857; http://dx.doi.org/10.1073/pnas.0812879106
   PubMed Web of Science ®Google Scholar
• Kabashima A, Higuchi H, Takaishi H, Matsuzaki Y, Suzuki S, Izumiya M, et al. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int J Cancer 2009; 124:2771 - 2779; PMID: 19296540; http://dx.doi.org/10.1002/ijc.24349
   PubMed Web of Science ®Google Scholar
• Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007; 67:2187 - 2196; PMID: 17332349; http://dx.doi.org/10.1158/0008-5472.CAN-06-3281
   PubMed Web of Science ®Google Scholar
• Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57:1420 - 1430; PMID: 18515410; http://dx.doi.org/10.1136/gut.2007.148189
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425:846 - 851; PMID: 14520411; http://dx.doi.org/10.1038/nature01972
   PubMed Web of Science ®Google Scholar
• Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 2007; 130:1120 - 1133; PMID: 17889654; http://dx.doi.org/10.1016/j.cell.2007.07.019
   PubMed Web of Science ®Google Scholar
• Bisht S, Feldmann G, Koorstra JB, Mullendore M, Alvarez H, Karikari C, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008; 7:3878 - 3888; PMID: 19074860; http://dx.doi.org/10.1158/1535-7163.MCT-08-0476
   PubMed Web of Science ®Google Scholar
• Feldmann G, Fendrich V, McGovern K, Bedja D, Bisht S, Alvarez H, et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol Cancer Ther 2008; 7:2725 - 2735; PMID: 18790753; http://dx.doi.org/10.1158/1535-7163.MCT-08-0573
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method. Methods 2001; 25:402 - 408; PMID: 11846609; http://dx.doi.org/10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar